×

Sofinnova closes €725 million fund to back European biotech expansion

By Thomson Reuters Nov 16, 2026 | 2:36 AM

By Bhanvi Satija

LONDON, Nov 16 (Reuters) – Life sciences investment firm Sofinnova Partners said on Monday it has closed a second crossover fund at €725 million ($799 million), above its original ​target, to back European biotechs that are seeking to ‌compete globally.

A crossover fund typically invests in private companies approaching commercialisation or public listings, bridging the gap between venture capital and public-market investing.

The raise comes at a time when drugmakers are pushing European governments to increase spending ‌on ​medicines, faster trials and other policies that ⁠would prevent the region ⁠from losing ground to the US and China.

At the same time, cash-strapped governments in Europe are under pressure to rethink how they pay for innovative medicines.

Europe has outstanding science and ​companies, said Kinam Hong, a partner at Sofinnova, told Reuters in an interview.

“It doesn’t have an innovation gap, but it ⁠really has a financing growth capital ⁠problem,” he said.

Hong said the fund, called Crossover II, ​is the biggest ever for the firm and will focus on ​European biotechs and medtech companies looking to commercialise their ‌medicines or devices, with some selective investments in the US and elsewhere.

Through the fund, Sofinnova expects to back about 15 companies and has already invested in rare-disease biotech Hemab Therapeutics, multiple myeloma ⁠drug developer CellCentric and Neurent Medical, a chronic rhinitis device maker.

Hong said the firm plans to be an active investor, helping companies with ⁠leadership, trials and ‌listings. He added that the aim is to ⁠build companies for “successful longevity” even without mergers and ​acquisitions.

The ‌firm’s first Crossover fund had backed Amolyt Pharma, ​a developer ⁠of treatments for rare hormone disorders that was acquired by AstraZeneca, as well as the French biotech Abivax, which is developing an ulcerative colitis drug.

Sofinnova manages more than €4 billion ($4.4 billion) in assets across healthcare and sustainability.

($1 = 0.9073 euros)

(Reporting by Bhanvi Satija in London, Editing ​by Louise Heavens)